NCT05223582 2023-12-08
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
Fudan University
Phase 2 Unknown
Clinical Trials
12 trialsNCT06161272 2023-12-07
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi
Guangxi Medical University
Phase 2 Unknown
NCT05585281 2023-07-28
A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT05932264 2023-07-06
Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT05928780 2023-07-03
An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)
Fudan University
Phase 1/2 Unknown
NCT05732129 2023-02-24
The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.
Fudan University
Phase 2 Unknown
NCT03805399 2022-08-10
FUTURE
Fudan University
Phase 1/2 Unknown
NCT04355858 2022-07-26
MULAN
Fudan University
Phase 2 Unknown
NCT04978012 2022-06-07
Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy
Fudan University
Phase 2 Unknown
NCT05170594 2021-12-28
A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer
The Second Affiliated Hospital of Shandong First Medical University
Phase 2 Unknown
NCT04828395 2021-05-11
F&C
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04659785 2020-12-09
A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）
Tianjin Medical University Second Hospital
Phase 1/2 Unknown